A New Antitumoral Agent: 9-Hydroxyellipticine. Possibility of a Rational Design of Anticancerous Drugs in the Series of DNA Intercalating Drugs
AUTOR(ES)
Le Pecq, Jean-Bernard
RESUMO
The designing of DNA intercalating drugs with high DNA affinity in the series of ellipticine has led to a new antitumoral agent, 9-hydroxyellipticine, which has a high DNA affinity, a high activity on L 1210 mice leukemia, and a lack of toxicity at therapeutic dose. The possible correlations among chemical structure, DNA reactivity, and pharmacological activity of DNA intercalating drugs are discussed.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=434043Documentos Relacionados
- Rational design of a triple helix-specific intercalating ligand
- Alpha Sarcin, a New Antitumor Agent: II. Fermentation and Antitumor Spectrum
- Rational Design of Drugs That Induce Human Immunodeficiency Virus Replication
- Alpha Sarcin, a New Antitumor Agent: I. Isolation, Purification, Chemical Composition, and the Identity of a New Amino Acid
- Nature of the Scrapie Agent: Evidence Against a Viroid
